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Abstract.  A new modality of targeted tumor chemotherapy is based on the drug encapsulation in 
polymeric nanoparticles followed by a localized release at the tumor site triggered by focused 
ultrasound. Effect of 1 MHz and 3 MHz unfocused ultrasound applied locally to the tumor on the 
Doxorubicin (DOX) biodistribution and tumor growth rates was measured for ovarian carcinoma 
tumors in nu/nu mice. The bioeffects of ultrasound were investigated on the systemic and cellular 
levels. Growth rates of A2780 ovarian carcinoma tumors were substantially reduced by 
combining micellar drug delivery with tumor irradiation. Ultrasound effect was not thermal as 
manifested by intratumoral temperature measurements during sonication. Biodistribution studies 
showed that ultrasound did not enhance micelle extravasation. Main mechanisms of the 
ultrasound-enhanced chemotherapy included (i) passive targeting of drug-loaded micelles to the 
tumor interstitium; (ii) ultrasound-triggered localized drug release from micelles in the tumor 
volume; (iii) enhanced micelle and drug diffusion through the tumor interstitium; and (iv) 




    
   A new modality of targeted chemotherapy that we are developing is based on the 
encapsulation of drug within polymeric nanoparticles followed by a localized release at 
the tumor site triggered by focused ultrasound. The rationale behind this approach is 
that drug encapsulation in nanoparticles decreases systemic drug exposure, diminishes 
intracellular drug uptake by normal cells, and provides for a passive drug targeting to 
tumors. Upon passive accumulation of drug-loaded nanoparticles in the tumor 
interstitium, tumor is irradiated by focused ultrasound, which triggers drug release from 
carriers and enhances the intracellular uptake of both released and encapsulated drug. 
Effect of local tumor sonication on drug biodistribution and tumor growth rates as well 
as mechanisms involved in the ultrasound action on the systemic and cellular levels are 
reported.  
 
MATERIALS AND METHODS 
 
Cells and animals. Human xenografts of ovarian carcinoma A2780 and colon cancer 
HCT116 tumors were inoculated subcutaneously (s.c.) in nu/nu mice. Biodistribution of 
drug (Doxorubicin, DOX) and tumor growth rates were measured in vivo for various 
drug delivery systems with and without tumors sonication.  
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Polymeric Micelles. Micelles formed by various block copolymers were studied. 
Pluronic P-105 is a triblock copolymer poly(ethylene oxide)-co-poly(propylene oxide)-
co-poly(ethylene oxide), with monomer unit ratio of 37/56/37. PEG-PBLA is a diblock 
copolymer of poly(ethylene oxide)-co-poly( -benzyl-L-aspartate); PEG2000-
diacylphospholipid is a PEGilated phospholipid used to stabilize Pluronic P-105 micelles 
against degradation upon i.v. injection. For studying micelle biodistribution, Pluronic P-
105 molecules were fluorescently labeled as described in ref. [1]. 
Sonication. Unfocused 1-MHz or 3-MHz ultrasound was generated by Omnisound 
3000 instrument. Ultrasound was applied through Aquasonic coupling gel for 30 s 
locally to s.c. tumors; for 1-MHz ultrasound, power density was 3.4 with 50% or 33% 
duty cycle; for 3-MHz ultrasound, power density was 1.8 W/cm2 with 100% duty cycle.  
Tumor sonication by focused 1.1 MHz ultrasound was performed using a submersible 
focused piezoceramic transducer (model H-101 S/N-29, Sonic Concepts, Woodinville, 
WA) producing a beam width of 1.5 mm at the focal site.  
Tumor growth rates 
A2780 cells were s.c. inoculated and tumors were allowed to develop and grow. 
Treatment was initiated when tumor volume reached at least 50 mm3. DOX was injected 
intravenously through the tail vein of a mouse at a dose of 3 mg/kg or 1.5 mg/kg. Three 
consecutive treatments were applied on days 1, 3, and 5. Ultrasound was applied locally 
to the tumor. Tumor volume was calculated based on the equation: V = (w)2 x (l)/2, 
where (w) and (l) are width and length of the tumor measured by a caliper. Between 
various treatment groups, growth rates were compared for the same initial tumor 
volumes at the start of the treatment.  
Micelle and DOX biodistribution. In micelle biodistribution experiments, 
fluorescently labeled mixed Pluronic/PEG2000-diacylphospholipid micelles were used. 
In DOX biodistribution studies, drug was encapsulated in unlabeled micelles. The time 
between drug injection and ultrasound application varied between 30 min and 12 hours. 
Ten minutes after the sonication, animals were sacrificed; tumors and various organs 
were excised, dried by filter paper, digested by trypsin, and fixed with 2.5% 
glutaraldehyde; after filtering through nylon mesh, cell fluorescence was measured by 
flow cytometry (FACSCAN, Becton Dickinson).  
 
RESULTS AND DISCUSSION 
 
A very significant degree of micelle targeting to tumor cells was observed for 
sonicated tumors (Figures 1 and 2). Ultrasonic treatment made micelle distribution in 
the tumor volume much more uniform (Figures 1). 
Biodistribution of micellar-encapsulated DOX followed that of micellar carrier, with 
a high degree of drug targeting to tumor cells (Figure 3).  
Ultrasound energy spreading beyond the tumor volume. As shown for the mixed 
micelles in Figure3 (left column), sonication of the tumor by unfocused 1-MHz 
ultrasound slightly increased DOX uptake by the other organ cells. This unwanted effect  
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Figure 1 (left). Fluorescence histograms of 
fluorescently labeled mixed micelles injected 
i.v. to A2780 tumor bearing mice; (A) - 
unsonicated and sonicated tumor cells; one 
tumor was sonicated for 30 s 4 h after the drug 
injection by 1-MHz ultrasound at 3.4 W/cm2 
power density;  (B) - tumor and heart cells in 
sonicated mouse; (C) – tumor and kidney cells 
in sonicated mouse. Thick lines correspond to 
sonicated cells. Fluorescence histograms of 
unsonicated tumor cells is bimodal, with a 
presence of low-uptake cells; in contrast, in 
sonicated tumor fluorescence histograms are 
unimodal and correspond to a higher uptake. 
Figure 2 (right). Phase contrast (bright) and 
fluorescence micrographs of various cells in 
sonicated mouse. 
 
Figure 3. DOX biodistribution in ovarian carcinoma tumor bearing mice upon injection of  micelle-
encapsulated DOX (6 mg/kg). Ultrasound frequency: left –1-MHz; right – 3-MHz . 
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 was caused by spreading ultrasound energy beyond the tumor volume. Direct 
measurements by a hydrophone confirmed that during a localized irradiation of the 
tumor with unfocused 1-MHz ultrasound, a significant fraction of the ultrasonic energy 
was delivered to other organs. The cause of this effect was that at the site opposite to the 
transducer, ultrasound waves were reflected from a skin/air interface back into the 
interior of a mouse body; plus, interior interfaces and bones located on the ultrasound 
path acted as reflection centers. This was not observed for 3-MHz ultrasound that was 
much more localized in the tumor volume (Figure 3, right column). Ultrasound spreading 
beyond the tumor volume due to scattering on interfaces and bones should be taken into 
consideration in clinical application of ultrasonically-enhanced drug delivery. Ultrasound 
focusing on the tumor would substantially reduce this problem. 
Effect of the time of ultrasound application. The extent of the ultrasonic enhancement 
of the intracellular DOX uptake depended on the time of ultrasound application after the 
drug injection. For DOX injected in PBS, the maximal effect of ultrasound was observed 
two to four hours after the drug injection. The effect was completely eliminated twenty 
four hours after the drug injection suggesting that little, if any DOX remained in the 
tumor interstitium.  
For DOX encapsulated in PEG-PBLA micelles, the effect of ultrasound constantly 
increased with increasing time between drug injection and ultrasound application. 
Thirty minutes after the drug injection, drug accumulation in the tumor cells was very 
low for both unsonicated and sonicated tumors, fluorescence of the tumor cells being 
close to the autofluorescence of the tumor cells in the control non-injected mice. With 
increasing time after the drug injection, fluorescence of the tumor cells and a difference 
between sonicated and non-sonicated tumors constantly increased; the ultrasound effect 
was very pronounced twelve hours after the drug injection; tumor sonication by 3-MHz 
ultrasound resulting in about 3-fold increase of DOX uptake by the tumor cells, as 
illustrated in Figure 3 (right).  A similar effect was observed for mixed micelles. This 
ruled out ultrasonic enhancement of micelle extravasation at the experimental 
conditions used here. If ultrasound enhanced micelle extravasation, some ultrasonic 
enhancement of the drug uptake by the tumor cells should have been observed at a 
short time after the drug injection, when a significant portion of the injected drug was 
still circulating. However, no effect of ultrasound was observed thirty minutes after the 
injection of micellar-encapsulated DOX, while a very strong ultrasound effects were 
observed for these micelles at later times, which was presumably associated with the 
effect of ultrasound on the micelles that had already accumulated in the tumor 
interstitium via the EPR effect.  
Thermal effects. Thermal effects could play a role in enhancing the intracellular 
drug uptake. However, at the experimental conditions used in experiments described 
above, a significant role of the thermal effects was ruled out by the direct intratumoral 
temperature measurements. In addition, for DOX encapsulated in mixed micelles, the 
effect of 60-s tumor sonication was compared to that of a 60-s tumor heating by 
“ironing”, to maintain a temperature of about 35oC for 30-s in the center of the tumor 
(this temperature is several degrees higher than the final tumor temperature reached 
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under ultrasound); even at these harsh heating conditions, the effect of ultrasound on 
the DOX intracellular uptake was significantly stronger than that of the tumor heating 
Effect of micellar delivery and ultrasound on the growth rates of s.c. ovarian 
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Figure 4. Tumor growth curves for 
A2780 tumors treated by 3 mg/kg 
DOX delivered in PBS or mixed 
micelles, with and without 
ultrasound. Localized tumor 
sonication by 1-MHz ultrasound 
was applied for 30 s 4 h after the 
drug injection at 3.4 W/cm2 power 
density and 33% duty cycle.  
 
Mechanisms of ultrasound bioeffects: systemic level. The study revealed following 
mechanisms involved in the ultrasound-enhanced chemotherapy i) passive targeting of 
drug-loaded micelles to the tumor interstitium; ii) ultrasound-triggered localized drug 
release from micelles in the tumor volume [3]; iii) enhanced micelle and drug diffusion 
through the tumor interstitium resulting in a more uniform drug distribution in the 
tumor volume; and iv) ultrasound-enhanced micelle and drug uptake by the tumor cells.  
At the experimental conditions, ultrasound did not enhance micelle extravasation. A 
significant role of the thermal effects was ruled out by direct intratumoral temperature 
measurement and by stronger effect of tumor sonication compared to tumor heating to 
approximately same final temperature [2]. 
Limitations of the intravenous drug delivery. The same micelle/ultrasound drug 
delivery technique failed in treating s.c. HCT116 colon cancer tumors. The reason of 
the treatment failure was a very poor tumor vascularization resulted in insufficient drug 
supply to tumor cells. For this tumor, successful treatment was achieved by direct 
intratumoral injections of micellar-encapsulated DOX combined with tumor sonication 




Combining micellar drug delivery with localized tumor sonication allows a high degree 
of drug targeting to tumor cells and uniform drug distribution over the tumor volume, 
which in turn, results in successful tumor chemotherapy. 
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